Status:
TERMINATED
Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)
Lead Sponsor:
Medical University of Vienna
Conditions:
Hyperthermia
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
Dantrolene is used to prevent hyperthermia in intensive care patients suffering from subarachnoidal hemorrhage.
Detailed Description
Background: Fever episodes occur in more than 50% of patients admitted to the ICU for subarachnoidal hemorrhage, central nervous system infection, seizure control, hemorrhagic stroke, and closed head...
Eligibility Criteria
Inclusion
- neurosurgical patients after subarachnoidal hemorrhage
- breathing spontaneously or being ventilator dependant
- sustained fever (≥38ºC for more than an hour) without an identifiable infectious cause.
Exclusion
- infection
- pregnancy
- arrhythmia
- muscular dystrophia
- acute liver disease
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2011
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00796900
Start Date
May 1 2008
End Date
March 1 2011
Last Update
May 12 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Vienna
Vienna, Austria, 1090